Reply
We thank Dr. Durante and colleagues for their interest in our paper (1) and their comments. Ischemic cardiomyopathy remains the most common etiology of systolic heart failure (2). In the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy) (3), 55% of patients had ischemic cardiomyopathy and 45% had nonischemic cardiomyopathy (NICM). This substrate distribution is similar to other contemporary early stage heart failure trials (4, 5) . The RAFT (Resynchronization/Defibrillation for Ambulatory Heart Failure Trial) recently showed that patients with ischemic or nonischemic causes of heart failure had a similar benefit from implantable cardioverter-defibrillator-cardiac resynchronization therapy in early-stage heart failure (6) .
For the sex substudy in the MADIT-CRT trial, we found 72% of the women had NICM as compared with 36% of men. Examining the NICM subgroup further, we found women had a significant reduction of the primary endpoint of heart failure and death (70%) or heart failure alone (69%), with significant interaction p values compared with men after receiving cardiac resynchronization therapy defibrillators (CRT-D). No prior study has demonstrated a significantly greater benefit from device therapy for women than men with regard to mortality or cardiac-related outcomes in an overall study population or by disease etiology.
It is possible that among patients with heart disease, the risk of heart failure is greater for women than for men, resulting in a greater benefit from preventive CRT-D therapy in women. Women might also have more dyssynchrony with equivalent QRS width compared with men. Of note, left bundle branch block (LBBB) was present in 70% of the MADIT-CRT patients, with 31% of the females having LBBB in this subset. Even within the LBBB subset, women had a significantly greater benefit from CRT-D than men after adjustment for relevant covariates (7) .
The findings from the MADIT-CRT trial with regard to the enhanced benefit in women when compared with men are quite strong. We doubt that a substrate matched trial of men and women with early-stage heart failure receiving CRT-D with equivalent rates of LBBB would further advance our knowledge in this area.
